Four Recent MPN Milestones Point to a Bigger Question: How Do We Measure Meaningful Progress?
The pace of innovation in myeloproliferative neoplasms (MPNs) continues to accelerate. Within a matter of weeks, the MPN community has seen a new Federal Drug Administration (FDA) approval for polycythemia vera (PV), an expanded indication for essential thrombocythemia (ET), a major manufacturing milestone affecting treatment access, and a regulatory filing that may further expand options for patients with myelofibrosis (MF).
Taken together, these developments reflect a field that is advancing on multiple fronts at once. They also highlight a broader question facing patients, clinicians, researchers, regulators, and industry alike.
Four Developments Reflecting Momentum Across the MPN Landscape
Takeda's approval of rusfertide for PV
The August approval of rusfertide (MIMRYLO™) introduced a first-in-class therapy designed to control hematocrit and reduce dependence on therapeutic phlebotomy in adults with PV. The approval was supported by data demonstrating improvement in fatigue.
Importantly, the approval reflects continued progress against challenges that significantly affect daily life for people living with PV. It also raises important questions about how symptom burden, treatment burden, and long-term disease outcomes should be balanced when evaluating therapeutic success.
PharmaEssentia's label expansion of BESREMi® into ET
Only days later, PharmaEssentia received FDA approval for BESREMi® in ET, marking the first new FDA-approved therapy for ET in nearly 3 decades. The approval expands treatment options for ET patients, a chronic blood cancer that has seen limited therapeutic innovation.
The discussion surrounding BESREMi also reflects an evolving interest in therapies that may extend beyond simple blood-count control. As understanding of MPN biology grows, researchers are increasingly interested in whether therapies can influence the course of an MPN’s disease course rather than solely managing symptoms or laboratory values.
pharma&'s manufacturing and supply-chain milestone for Pegasys®
Not every important development in MPN care comes in the form of a new drug approval. The FDA approved a Prior Approval Supplement (PAS) for Pegasys® that added Loba biotech GmbH, a wholly owned manufacturing subsidiary of pharma&, as a site for production of peginterferon alfa-2a, the therapy's active pharmaceutical ingredient. The approval is intended to support a stable and reliable, long-term U.S. supply and continuity of care for eligible patients.
While manufacturing announcements may receive less attention than clinical trial results, treatment access remains a critical part of the patient experience. Scientific innovation creates opportunity only when patients can reliably obtain and continue therapy. This milestone highlights the importance of infrastructure, manufacturing resilience, and long-term planning as components of quality care.
Karyopharm's myelofibrosis filing and the endpoint conversation
Karyopharm's supplemental New Drug Application for selinexor plus ruxolitinib may ultimately be remembered not only for the therapy itself, but also for the conversation it has sparked regarding clinical trial endpoints. The company's filing highlights findings related to spleen responses, overall survival signals, and evidence they characterize as disease modification. It also relies on the proposition that spleen volume reduction may serve as a surrogate endpoint connected to long-term clinical benefit.
Looking Beyond Individual Milestones
Each of these developments represent progress. Collectively, however, they point to something larger.
The MPN field appears to be moving from an era primarily focused on controlling blood counts and managing symptoms toward one increasingly focused on deeper biological questions.
Can therapies alter the trajectory of disease?
Can progression be delayed or prevented?
Which biomarkers best reflect meaningful benefit?
Which endpoints most accurately predict outcomes that matter to patients?
These questions are not only academic. Their answers will influence future trial design, regulatory pathways, treatment decisions, and ultimately the patient experience.
How should the MPN community define meaningful clinical benefit in the next generation of therapies?
Across the MPN field, researchers, clinicians, regulators, and industry leaders are increasingly evaluating whether traditional endpoints fully capture the outcomes that matter most. Recent discussions at MPN Research Foundation's MPN Roundtable™ emphasized the need for endpoints that reflect meaningful clinical benefit, real-world value, and disease progression. Leaders in the field also highlighted the importance of validating surrogate endpoints through collaboration and data sharing.
For MPN Research Foundation, this moment is an opportunity to consider how stakeholders can work together to ensure that innovation translates into better outcomes for patients. MPN Research Foundation has long positioned itself as a neutral convener that brings together patients and caregivers, researchers and clinicians, and the biopharmaceutical industry to align scientific goals with patient needs.
A Need for More Intentional Engagement
“With the growing pipeline of new agents and each new approval, MPN Research Foundation’s long-standing approach to intentional engagement across the ecosystem continues to hold value,” states MPN Research Foundation’s CEO, Kapila Viges. She continues, saying, “Our convening role goes beyond facilitating meetings. With our growing knowledge of the evolving disease landscape, we have the opportunity and obligation to discuss, help define, and enable delivery of meaningful benefit.”
Bringing those perspectives together helps ensure that the field advances toward outcomes that are scientifically rigorous, clinically meaningful, and relevant to everyday patient experiences.
The past several weeks demonstrate the strength of the current MPN pipeline. They also reinforced the importance of continued collaboration. MPN Research Foundation welcomes that conversation and remains committed to helping lead it.
Sources
Takeda Pharmaceutical Company Limited. (2026, August 28). Takeda receives U.S. FDA approval of MIMRYLO™ (rusfertide), marking a potential shift in the treatment paradigm for polycythemia vera. https://www.takeda.com/newsroom/newsreleases/2026/fda-approval-mimrylo/
PharmaEssentia USA Corporation. (2026, August 31). FDA approves PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for adults with essential thrombocythemia, a rare blood cancer. https://us.pharmaessentia.com/fda-approves-pharmaessentias-besremi-ropeginterferon-alfa-2b-njft-for-adults-with-essential-thrombocythemia-a-rare-blood-cancer/
pharmaand GmbH. (2026, August 19). pharma& receives FDA approval for Pegasys® prior approval supplement, adding Loba biotech for API production to ensure stable long-term supply in the United States [Press release]. https://www.pharmaand.com/wp-content/uploads/2026/08/News-Release_FDA-PAS-Loba-approval-for-Pegasys-FINAL-19Aug2026.pdf
Karyopharm Therapeutics Inc. (2026, August 31). Karyopharm submits supplemental new drug application to the FDA for XPOVIO® (selinexor) plus ruxolitinib for patients with myelofibrosis. https://investors.karyopharm.com/2026-08-31-Karyopharm-Submits-Supplemental-New-Drug-Application-to-the-FDA-for-XPOVIO-R-selinexor-Plus-Ruxolitinib-for-Patients-with-Myelofibrosis